Evidence map›Paper›PMID 32194572›Full record

ReviewFrontiers in immunology2020

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.

Yi-Shu Huang, Joy Ogbechi, Felix I Clanchy, Richard O Williams, Trevor W Stone

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 3 syntheses or guidelines pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Monocolonization withMicrobiology spectrum · 2026
    Article
  13. Review
  14. Rewiring the Lung-CNS Axis After Spinal Cord Injury.Journal of inflammation research · 2026
    Review
  15. Metabolomics of HIV in the Modern cART Era.Advances in experimental medicine and biology · 2026
    Review
  16. Frontiers in cellular neuroscience · 2026
    Review
  17. Tryptophan's Journey Through Pregnancy: The Role of Serotonin.International journal of tryptophan research : IJTR · 2026
    Review
  18. Review
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yi-Shu HuangThe Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, United Kingdom.
Joy OgbechiThe Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, United Kingdom.
Felix I ClanchyThe Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, United Kingdom.
Richard O WilliamsThe Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, United Kingdom.
Trevor W StoneThe Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, United Kingdom.
University of Oxford · GB

Funding

Cancer Research UK
6 · The paper itself

Abstract

The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis. Indoleamine-2,3-dioxygenase (IDO) activity exerts a protective function, limiting the severity of experimental arthritis, whereas deletion or inhibition exacerbates the symptoms. Other chronic disorder with an inflammatory component, such as atherosclerosis, are also suppressed by IDO activity. It is suggested that this overall anti-inflammatory activity is mediated by a change in the relative production or activity of Th17 and regulatory T cell populations. Kynurenines may play an anti-inflammatory role also in CNS disorders such as Huntington's disease, Alzheimer's disease and multiple sclerosis, in which signs of inflammation and neurodegeneration are involved. The possibility is discussed that in Huntington's disease kynurenines interact with other anti-inflammatory molecules such as Human Lymphocyte Antigen-G which may be relevant in other disorders. Kynurenine involvement may account for the protection afforded to animals with cerebral malaria and trypanosomiasis when they are treated with an inhibitor of kynurenine-3-monoxygenase (KMO). There is some evidence that changes in IL-10 may contribute to this protection and the relationship between kynurenines and IL-10 in arthritis and other inflammatory conditions should be explored. In addition, metabolites of kynurenine downstream of KMO, such as anthranilic acid and 3-hydroxy-anthranilic acid can influence inflammation, and the ratio of these compounds is a valuable biomarker of inflammatory status although the underlying molecular mechanisms of the changes require clarification. Hence it is essential that more effort be expended to identify their sites of action as potential targets for drug development. Finally, we discuss increasing awareness of the epigenetic regulation of IDO, for example by DNA methylation, a phenomenon which may explain differences between individuals in their susceptibility to arthritis and other inflammatory disorders.

Indexed as

AnimalsHumansIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineNervous System DiseasesIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenine3-hydroxyanthranilic acidarthritisHuntington's diseasekynureninelymphocyte antigensT-cells

Identifiers

PMID32194572
PMCPMC7066259
OpenAlexW3009619005

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.